The prodrug platin-A: simultaneous release of cisplatin and aspirin.
The prodrug platin-A: simultaneous release of cisplatin and aspirin.
复制标题
DOI：
10.1002/anie.201308899
复制
发表时间：
2014-02-10
期刊：
影响因子：
--
通讯作者：
Dhar, Shanta
中科院分区：
文献类型：
--
作者：
Pathak, Rakesh K;Marrache, Sean;Dhar, Shanta
癌症相关炎症诱导肿瘤进展到转移阶段，因此表明化疗抗炎策略对侵袭性癌症的治疗是有意义的。铂(IV)前体药物Platin-A旨在释放顺铂和阿司匹林，以减轻顺铂引起的肾毒性和耳毒性。Platin-A显示出比顺铂和阿司匹林组合更好的抗癌和抗炎特性。这些发现突出了抗炎治疗与化疗相结合的优势，因为这两种药物都是以单一前体药物的形式提供的。
Cancer-associated inflammation induces tumor progression to the metastatic stage, thus indicating that a chemo-anti-inflammatory strategy is of interest for the management of aggressive cancers. The platinum(IV) prodrug Platin-A was designed to release cisplatin and aspirin to ameliorate the nephrotoxicity and ototoxicity caused by cisplatin. Platin-A exhibited anticancer and anti-inflammatory properties which are better than a combination of cisplatin and aspirin. These findings highlight the advantages of combining anti-inflammatory treatment with chemotherapy when both the drugs are delivered in the form of a single prodrug.